Quadrivalent influenza vaccines are on the way. MedImmune and Sanofi Pasteur have announced they have begun shipment of their respective quadrivalent vaccines for the 2013-2014 season following release by the FDA for US distribution.
The 2013-2014 influenza season will be the first season to embrace quadrivalent vaccines. MedImmune's intra-nasal FluMist Quadrivalent, Sanofi's Fluzone Quadrivalent and Glaxo's Fluarix Quadrivalent each contain a second B strain to help protect against influenza disease. Previous trivalent formulations contained only one B strain, but the B strain in circulation each season has been difficult to predict.
However, with the number of flu shot options available this seasons, do you think that consumers and healthcare providers could become confused by the choices? Leave a comment in the box below, or on our LinkedIn group discussion.
Sign up to the Vaccine Nation newsletter for more insights into strategy and innovation in vaccines.
If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, attend the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille.